X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2810) 2810
Publication (486) 486
Book Review (302) 302
Book Chapter (10) 10
Conference Proceeding (10) 10
Web Resource (4) 4
Book / eBook (2) 2
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2629) 2629
humans (2098) 2098
bortezomib (1935) 1935
boronic acids - pharmacology (1870) 1870
pyrazines - pharmacology (1474) 1474
animals (933) 933
antineoplastic agents - pharmacology (853) 853
cell line, tumor (782) 782
oncology (776) 776
apoptosis - drug effects (678) 678
apoptosis (633) 633
proteasome inhibitors (556) 556
mice (554) 554
female (508) 508
male (492) 492
boronic acids - therapeutic use (483) 483
cancer (470) 470
protease inhibitors - pharmacology (464) 464
multiple myeloma - drug therapy (462) 462
pyrazines - therapeutic use (454) 454
boronic acids - chemistry (415) 415
pharmacology & pharmacy (392) 392
boronic acids - administration & dosage (351) 351
hematology (348) 348
multiple myeloma (345) 345
multiple-myeloma (334) 334
biochemistry & molecular biology (327) 327
pyrazines - administration & dosage (322) 322
proteasome endopeptidase complex - metabolism (315) 315
antineoplastic agents - therapeutic use (312) 312
cell proliferation - drug effects (305) 305
drug synergism (300) 300
chemistry, medicinal (284) 284
nf-kappa-b (275) 275
article (255) 255
dose-response relationship, drug (243) 243
middle aged (243) 243
multiple myeloma - pathology (242) 242
activation (239) 239
proteins (228) 228
research (222) 222
aged (221) 221
boronic acids (210) 210
expression (210) 210
cell survival - drug effects (206) 206
nf-kappa b - metabolism (205) 205
enzyme inhibitors - pharmacology (197) 197
cell biology (196) 196
antineoplastic combined chemotherapy protocols - therapeutic use (195) 195
proteasome (191) 191
multiple myeloma - metabolism (182) 182
proteasome inhibitors - pharmacology (179) 179
structure-activity relationship (178) 178
proteasome inhibitor bortezomib (175) 175
abridged index medicus (171) 171
analysis (171) 171
proteasome inhibitor (170) 170
adult (169) 169
tumor cells, cultured (168) 168
blotting, western (167) 167
drug resistance, neoplasm (164) 164
molecular structure (164) 164
boronic acids - adverse effects (162) 162
cells (159) 159
chemotherapy (159) 159
therapy (159) 159
treatment outcome (156) 156
xenograft model antitumor assays (155) 155
pyrazines - adverse effects (154) 154
hemic and lymphatic diseases (153) 153
in-vivo (151) 151
boronic acid (150) 150
multiple-myeloma cells (148) 148
signal transduction - drug effects (147) 147
resistance (146) 146
protease inhibitors - therapeutic use (143) 143
in-vitro (141) 141
antineoplastic combined chemotherapy protocols - pharmacology (137) 137
cells, cultured (137) 137
rats (135) 135
phosphorylation (134) 134
chemistry, organic (130) 130
induced apoptosis (129) 129
neoplasms - drug therapy (129) 129
health aspects (128) 128
cell line (124) 124
care and treatment (123) 123
signal transduction (122) 122
ps-341 (121) 121
growth (120) 120
chemistry, multidisciplinary (119) 119
drug therapy (115) 115
pathway (115) 115
down-regulation (114) 114
inhibition (114) 114
proteasome inhibition (114) 114
tumors (113) 113
flow cytometry (111) 111
time factors (111) 111
drug design (110) 110
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2696) 2696
Chinese (77) 77
Japanese (23) 23
French (10) 10
German (6) 6
Spanish (5) 5
Russian (3) 3
Hungarian (1) 1
Polish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2015, Volume 58, Issue 9, pp. 3682 - 3692
Journal Article
Cancer Cell, ISSN 1535-6108, 09/2012, Volume 22, Issue 3, pp. 345 - 358
Bortezomib therapy has proven successful for the treatment of relapsed/refractory, relapsed, and newly diagnosed multiple myeloma (MM); however, dose-limiting... 
DEUBIQUITINATING ENZYME | INACTIVATION | PROTEIN | THERAPY | ONCOLOGY | MDM2 | DEGRADATION | MECHANISMS | HAUSP | CANCER | P53 REGULATION | CELL BIOLOGY | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Molecular Sequence Data | Antineoplastic Agents - therapeutic use | Pyrazines - therapeutic use | Thalidomide - pharmacology | Boronic Acids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Protease Inhibitors - pharmacology | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Dexamethasone - pharmacology | Antineoplastic Agents - pharmacology | Drug Therapy, Combination | Multiple Myeloma - enzymology | Protease Inhibitors - therapeutic use | Proto-Oncogene Proteins c-mdm2 - metabolism | Ubiquitin Thiolesterase - antagonists & inhibitors | Bortezomib | Cyclin-Dependent Kinase Inhibitor p21 - antagonists & inhibitors | Thiophenes - pharmacology | Random Allocation | Mice, SCID | Ubiquitin Thiolesterase - genetics | Xenograft Model Antitumor Assays | Dexamethasone - therapeutic use | Multiple Myeloma - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Mice | Thalidomide - therapeutic use | Pyrazines - pharmacology | Ubiquitin-Specific Peptidase 7 | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Medical colleges | Dexamethasone | Proteases | Analysis | Multiple myeloma | Lymphomas | Apoptosis | Index Medicus
Journal Article
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 11, pp. 2579 - 2589
Journal Article
Autophagy, ISSN 1554-8627, 08/2014, Volume 10, Issue 8, pp. 1380 - 1390
Journal Article
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 18, pp. 4771 - 4779
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 7/2014, Volume 111, Issue 28, pp. 10287 - 10292
Bone is a favorable microenvironment for tumor growth and a frequent destination for metastatic cancer cells. Targeting cancers within the bone marrow remains... 
Nanoparticles | Femur | Emulsions | Antineoplastics | Multiple myeloma | Fluorescence | Bones | Pretreatment | Polymers | Cancer | Alendronate-PLGA-PEG | Targeting nanomedicine | Bisphosphonate | Bone metastasis | MULTIPLE-MYELOMA | CELLS | DEXAMETHASONE | ACTIVATION | bone metastasis | VIVO | MULTIDISCIPLINARY SCIENCES | BORTEZOMIB | ANTITUMOR-ACTIVITY | targeting nanomedicine | IN-VITRO | THERAPY | PATHWAY | alendronate-PLGA-PEG | bisphosphonate | Neoplasm Transplantation | Polyglycolic Acid - chemical synthesis | Nanoparticles - chemistry | Humans | Polyglycolic Acid - pharmacology | Polyethylene Glycols - chemistry | Boronic Acids - chemistry | Bone Neoplasms - pathology | Alendronate - chemistry | Bone Neoplasms - metabolism | Drug Delivery Systems | Neoplasms, Experimental - pathology | Multiple Myeloma - drug therapy | Heterografts | Antineoplastic Agents - pharmacology | Bone Neoplasms - drug therapy | Lactic Acid - pharmacology | Tumor Microenvironment - drug effects | Bortezomib | Lactic Acid - chemistry | Nanoparticles - ultrastructure | Polyethylene Glycols - pharmacokinetics | Antineoplastic Agents - chemistry | Multiple Myeloma - metabolism | Xenograft Model Antitumor Assays | Pyrazines - chemistry | Multiple Myeloma - pathology | Animals | Mice, Nude | Polyglycolic Acid - chemistry | Cell Line, Tumor | Mice | Mice, Inbred BALB C | Polyethylene Glycols - chemical synthesis | Lactic Acid - chemical synthesis | Neoplasms, Experimental - metabolism | Pyrazines - pharmacology | Neoplasms, Experimental - drug therapy | Boronic Acids - pharmacology | Bone marrow | Metastasis | Polyethylene glycol | Rodents | Tumors | Index Medicus | Biological Sciences | Physical Sciences
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 2014, Volume 10, Issue 8, pp. 656 - 663
Journal Article
Blood, ISSN 0006-4971, 04/2013, Volume 121, Issue 15, pp. 2975 - 2987
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been... 
CANCER-PATIENTS | DENDRITIC CELLS | T-REGULATORY CELLS | IMMUNOSUPPRESSION | BONE-MARROW | GROWTH | PERIPHERAL-BLOOD | DIFFERENTIATION | IDENTIFICATION | HEMATOLOGY | PROGRESSION | Cell Proliferation | Reactive Oxygen Species - metabolism | Coculture Techniques | Humans | Sialic Acid Binding Ig-like Lectin 3 - immunology | Multiple Myeloma - immunology | Thalidomide - pharmacology | Lewis X Antigen - metabolism | Lipopolysaccharides - immunology | Thalidomide - analogs & derivatives | Flow Cytometry | T-Lymphocytes - metabolism | Myeloid Cells - immunology | Reactive Oxygen Species - immunology | Myeloid Cells - drug effects | Antineoplastic Agents - pharmacology | HLA-DR Antigens - metabolism | Sialic Acid Binding Ig-like Lectin 3 - metabolism | Cytokines - immunology | Tumor Microenvironment - drug effects | Bortezomib | CD11b Antigen - immunology | Cytokines - metabolism | Cells, Cultured | Lewis X Antigen - immunology | Multiple Myeloma - metabolism | Tumor Microenvironment - immunology | Multiple Myeloma - pathology | Lipopolysaccharides - pharmacology | Cell Line, Tumor | Myeloid Cells - metabolism | T-Lymphocytes - immunology | HLA-DR Antigens - immunology | CD11b Antigen - metabolism | Pyrazines - pharmacology | Immunologic Factors - pharmacology | Boronic Acids - pharmacology | Tumor Burden - immunology | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia
Journal Article
Journal Article